Elan Corporation

Pharmaceutical company

9/7/2008 17:50 ET

Site Map | Contact Us | Search:

  • NYSE | ELN | 12.96 | +0.18  (20 minute delay)
 Read the full President and CEO's Statement  

 

 


               These are large files please allow sufficient time to download

Feature:

  • Elan And Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology...more
  • Elan's Half-Yearly Financial Report...more
  • WEBCAST REPLAY: Elan and Biogen Idec Will Host a Conference Call for the Investment Community...more 
  • WEBCAST REPLAY: Elan and Wyeth Discuss Bapineuzumab Phase 2 Clinical Trial Results...more                

Marketed Products
in the U.S.

  • TYSABRI®
    (natalizumab)
  • PRIALT®
    (ziconotide intrathecal infusion) 
  • Azactam®
    (aztreonam for injection, USP)
  • Maxipime®
    (cefepime hydrochloride) for injection                      

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use